Question 1

Am I eligible for this trial based on my treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment clinical trial (NCT05479487). Contact the study team or your healthcare provider for specific answers.

Question 2

How does the combination of fluzoparib and apatinib compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment clinical trial (NCT05479487). Contact the study team or your healthcare provider for specific answers.

Question 3

What are the potential side effects of the treatments being tested?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment clinical trial (NCT05479487). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for visits if I participate?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment clinical trial (NCT05479487). Contact the study team or your healthcare provider for specific answers.

Question 5

What happens if my cancer progresses during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment clinical trial (NCT05479487). Contact the study team or your healthcare provider for specific answers.

Question 6

Are there any additional costs or logistical considerations I should be aware of?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment clinical trial (NCT05479487). Contact the study team or your healthcare provider for specific answers.

What this study is about